metaEvidence - overview


			objective responses (ORR)
la/mBC - HR positive - L2 - PIK3CA mutant breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2) la/mBC - HR positive - L2 - PIK3CA mutant
versus fulvestrant
	buparlisib plus fulvestrant vs. fulvestrant	1	1.34 [0.66; 2.71], 1 RCT, I2=0% inconclusive result